My take is that we will see it used on cell therapies like CAR-T. Id point out that Novartis and Intellia have signed a deal to this effect - see link below. I

My take is that we will see it used on cell therapies like CAR-T. Id point out that Novartis and Intellia have signed a deal to this effect - see link below. Immunotherapy is likely a clear win for this kind of genome editing technology. Any sort of ex vivo modification and repatriation of cells (like bone marrow transplants) are a good fit. Personal eugenics is extremely unlikely in the West. It is also very far away because of this regulatory burden. Id just point out that there are cases where you might find this kind of thing permissible. For instance the other day a friend of mine who went through IVF with his wife said "imagine if we had one good embryo from three rounds of IVF, and that one embryo had cystic fibrosis - would you really be comfortable stopping me from repairing that?" I found it hard to say "yes we should stop that". But I also recognise that if we allow that, its only a small leap to allow anyone to edit anything they want, for whatever reason. Drawing the lines will be tough. For the deal I mentioned: http://www.xconomy.com/boston/2015/01/07/cart-crispr-1st-of-its-kind-biotech-deal-from-novartis-intellia/ http://www.xconomy.com/boston/2015/01/07/cart-crispr-1st-of-...